Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they take when funding medical research to ensure that diseases common to males and females are studied on a separate gender basis rather than a male-only basis.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Through our National Institute for Health and Care Research (NIHR), we are actively committed to ensuring there is more research into women’s health, and that women’s voices and priorities are placed at the heart of this research.

We know that women have been under-represented in some research areas, particularly women in ethnic minority groups, older women, women of reproductive age, disabled women and LGBT+ women. This has implications for the health and care they receive, their options and awareness of treatments, the support they can access afterwards, and their health outcomes. To address this gap, applicants are now required to build inclusion into their research design as a condition of NIHR funding.

As highlighted in the newly published Renewed Women’s Health Strategy for England, the Department has strengthened NIHR conditions of funding by making it mandatory for researchers to account for sex and gender in their research applications. This move aims to tackle significant and persistent gaps in health and care research.

Alongside this, the NIHR’s Research Inclusion Strategy 2022-2027 sets out how NIHR will become a more inclusive funder of research and widen access to participation in clinical trials. The strategy has been designed to address inequalities associated with the protected characteristics of the Equality Act 2010.

Through the ongoing systematic collection of data on sex, ethnicity and age of participants taking part in NIHR research, we can monitor progress and continue to champion the inclusion of under-represented groups.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of whether a health gap for females is caused by bias in medical research.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Through our National Institute for Health and Care Research (NIHR), we are actively committed to ensuring there is more research into women’s health, and that women’s voices and priorities are placed at the heart of this research.

We know that women have been under-represented in some research areas, particularly women in ethnic minority groups, older women, women of reproductive age, disabled women and LGBT+ women. This has implications for the health and care they receive, their options and awareness of treatments, the support they can access afterwards, and their health outcomes. To address this gap, applicants are now required to build inclusion into their research design as a condition of NIHR funding.

As highlighted in the newly published Renewed Women’s Health Strategy for England, the Department has strengthened NIHR conditions of funding by making it mandatory for researchers to account for sex and gender in their research applications. This move aims to tackle significant and persistent gaps in health and care research.

Alongside this, the NIHR’s Research Inclusion Strategy 2022-2027 sets out how NIHR will become a more inclusive funder of research and widen access to participation in clinical trials. The strategy has been designed to address inequalities associated with the protected characteristics of the Equality Act 2010.

Through the ongoing systematic collection of data on sex, ethnicity and age of participants taking part in NIHR research, we can monitor progress and continue to champion the inclusion of under-represented groups.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the inequalities affecting women identified in the report by Warwick University and Cysters, Women’s reproductive health in the West Midlands, published in March.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

We were dismayed to read the findings of this report, which highlights the deep inequalities faced in accessing gynaecological care by women in the West Midlands. The Government agrees with the conclusion of the report that every woman deserves access to timely and high-quality care. That is why we will not accept these kinds of disparities as inevitable. Our ambition is a fairer Britain, where people live well for longer and spend less time in ill health, and where women, whatever their background, can rely on high-quality care.

We are shifting the centre of gravity of care from hospitals to communities, with neighbourhood services designed around local need.

Earlier this month, we published a Neighbourhood Health Framework setting out three reform agendas for integrated care boards (ICBs), local authorities, and civil society to deliver the aims of neighbourhood health: to improve services for people who need routine healthcare; to improve proactive care including maintaining and developing access to women's health services; and to deliver better alternatives to hospital care.

The framework provides clarity and consistency, supporting joined-up partnership between ICBs and local authorities, working together to develop locally led neighbourhood health plans.

We have made strong progress in turning the commitments in the last administration’s Women's Health Strategy into tangible action. Our renewed strategy will address gaps from the 2022 strategy, and go further to create a system that listens to women and tackles health inequalities across England.

Renewing the strategy will help identify and remove enduring barriers to high-quality care across England, such as long waits for diagnosis, and will ensure that professionals listen and respond to women’s needs.

This short inquiry will consider pet parasite medication (PPM), with a focus on treatments containing pesticides of concern such as fipronil and imidacloprid. The inquiry will seek to understand distribution pathways, and the impact of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and pet owners of alternative medications or application practices.